Benitec Biopharma Inc. (BNTC)
NASDAQ: BNTC · Real-Time Price · USD
9.07
+0.20 (2.25%)
Oct 12, 2026, 4:00 PM EDT - Market closed
Benitec Biopharma Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
24
Market Cap
316.39M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2026 | - | - | - |
| Jun 30, 2025 | - | - | - |
| Jun 30, 2024 | - | - | - |
| Jun 30, 2023 | 75.00K | 2.00K | 2.74% |
| Jun 30, 2022 | 73.00K | 14.00K | 23.73% |
| Jun 30, 2021 | 59.00K | -43.00K | -42.16% |
| Jun 30, 2020 | 102.00K | -12.10M | -99.16% |
| Jun 30, 2019 | 12.20M | 8.81M | 259.85% |
| Jun 30, 2018 | 3.39M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Fulcrum Therapeutics | 80.00M |
| Clinuvel Pharmaceuticals | 65.05M |
| Abeona Therapeutics | 25.52M |
| X4 Pharmaceuticals | 15.85M |
| Ocugen | 4.58M |
| EyePoint | 2.79M |
| Artiva Biotherapeutics | 251.00K |
BNTC News
- 7 days ago - Benitec Biopharma says BB-301 pivotal still on track for mid-2027 - TheFly
- 7 days ago - Benitec Biopharma Announces Regulatory Update Following Type C Meeting with FDA for BB-301 Pivotal Study - GlobeNewsWire
- 27 days ago - Benitec Biopharma price target raised to $17 from $16 at Wedbush - TheFly
- 27 days ago - Benitec Biopharma price target raised to $17 from $16 at Wedbush - TheFly
- 4 weeks ago - Benitec Biopharma files $200M mixed securities shelf - TheFly
- 4 weeks ago - Benitec Biopharma Releases Full Year 2026 Financial Results and Provides Operational Update - GlobeNewsWire
- 4 weeks ago - Benitec Biopharma Earnings release: Q4 2026 - Filings
- 4 weeks ago - Benitec Biopharma Annual report: Q4 2026 - Filings